Left ventricular assist devices (LVADs) have revolutionized the management of advanced heart failure, shifting from early pulsatile pumps to modern, magnetically levitated continuous-flow systems like the HeartMate 3. These devices significantly improve survival and quality of life, though they remain associated with risks such as driveline infections and right ventricular failure. Surgical success depends heavily on intraoperative management, including optimizing right ventricular geometry and minimizing ischemic time. While heart transplantation remains the gold standard, LVADs serve as critical destination therapy for patients ineligible for transplant. Future innovations focus on developing fully implantable systems, improving battery efficiency, and refining patient selection to address the population of heart failure patients who currently lack viable treatment options. Experts Dr. Jeff Teuteberg and Dr. Mani Daneshmand emphasize that while the technology has advanced, the field requires further research into long-term management and recovery strategies.
Sign in to continue reading, translating and more.
Continue